Compass Therapeutics Investor Presentation Deck slide image

Compass Therapeutics Investor Presentation Deck

Phase 2 U.S. CRC Study Design COMPASS THERAPEUTICS Simon 2 Stage Adaptive Design Stage 1 Stop Recruitment Stage 2 No n = 37 subjects ORR > 3/37 Yes n = 47 subjects 26
View entire presentation